Predicting Bleeding Risk in Acute Myeloid Leukemia With Thrombocytopenia With Platelet Function Tests
Platelet aggregation and platelet activation were both independently associated with bleeding risk.
Acute Myeloid Leukemia
Evaluating the Cost-Effectiveness of Acute Myeloid Leukemia Treatment
The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.
Heparin Derivative CX-01 May Boost Standard AML Induction
The new findings suggest that CX-01 may strengthen the efficacy of standard AML induction.
Study Found Gilteritinib Superior to Salvage Chemotherapy in FLT3-Mutated Refractory AML
The researchers examined 37 recurrently mutated genes in AML using next-generation sequencing.
Update from AACR: Divergent Data on FLT3 Inhibitors Tell a Tale of 2 Outcomes in AML and mCRC
Several preclinical studies provided more refined and nuanced insights into the target itself, and bioinformatics uncovered a way to measure low levels of residual disease during morphologic remission.
Similar Health Care Costs in Older Patients With AML Regardless of Induction Intensity
A similar number of transfusions were required in older patients with AML receiving intensive induction therapy versus single-agent azacitadine or decitabine.
FDA Panel Backs Pexidartinib for Rare Tumor, Votes Against Quizartinib for FLT3-ITD AML
The Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee recently voted on 2 investigational therapies being developed by Daiichi Sankyo: pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT), and quizartinib for the treatment of adults with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML).
Predicting Survival of Certain Subgroups of Patients With AML Following Allogeneic SCT
Based on the results of this study, a new risk stratification system was developed to facilitate prediction of posttransplant survival in patients with AML-MDC.
Biological Differences Between 2 Rare Leukemias Do Not Influence Clinical Outcomes
The classification of acute leukemia according to WHO criteria as undifferentiated or minimally differentiated did not appear to have an effect on overall outcomes.
Tibsovo Approved to Treat Newly Diagnosed AML With IDH1 Mutation
The FDA has expanded the indication for Tibsovo to include treatment of newly diagnosed acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
Next post in Hematologic Cancers
